SEC Form 20-F filed by PRF Technologies Ltd.
$PRFX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today provided a business update for the year ended December 31, 2025, in conjunction with the filing of its Annual Report on Form 20-F. 2025 and early 2026 Highlights Completed the strategic acquisition of DeepSolar, expanding PRF into AI-driven solar analytics and establishing a second high-growth operating platform.Completed a majority investment in LayerBio, adding OcuRing™-K, a patented drop-less, susta
TEL AVIV, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today announced a commercial collaboration agreement with Blade Ranger Ltd. (TASE: BLRN) designed to accelerate the commercial expansion of its DeepSolar platform across utility-scale solar portfolios. The commercial collaboration agreement is structured to support the introduction and negotiation of multiple large-scale commercial engagements for DeepSolar, each with a minimum scope of 150 megawatts (MW), representing significant potential enterprise-level deployments. Blade Ranger operates at the intersection of renewable energy development, asset optimization, and infrastr
TEL AVIV, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced that its DeepSolar business unit has entered into a solar analytics services agreement with a subsidiary of EDF Group (Electricite' De France, France's Electric Company, one of the largest international energy companies), a global leader in renewable energy, relating to an operational, utility-scale solar power plant in Israel. This engagement represents the next phase of Deep Solar's previously announced strategy and a new commercial revenue opportunity—an important milestone following the recent launch of Smart TDD. Pursuant to the agre
6-K - PRF Technologies Ltd. (0001801834) (Filer)
20-F - PRF Technologies Ltd. (0001801834) (Filer)
6-K - PRF Technologies Ltd. (0001801834) (Filer)
3 - PRF Technologies Ltd. (0001801834) (Issuer)
3 - PRF Technologies Ltd. (0001801834) (Issuer)
3 - PRF Technologies Ltd. (0001801834) (Issuer)
SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)
SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)
SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)
HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update. Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri
HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing
LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today provided a business update for the year ended December 31, 2025, in conjunction with the filing of its Annual Report on Form 20-F. 2025 and early 2026 Highlights Completed the strategic acquisition of DeepSolar, expanding PRF into AI-driven solar analytics and establishing a second high-growth operating platform.Completed a majority investment in LayerBio, adding OcuRing™-K, a patented drop-less, susta